Core Accelerates and a New CEO Sets the Agenda, but the Discount Is Gone: Downgrading Danaher to Hold

Results vs. Consensus

Q3 2026 Scorecard

Year-Over-Year Comparison

Quarter-Over-Quarter Comparison

Quality of Beat

Revenue: In line on the headline, better underneath. Reported revenue of $6,554M rose 8.3%, with Masimo adding roughly 6.5 points and currency neutral. Tariff refunds that Danaher returned to customers reduced reported sales by about 1 point at the company level and about 4 points in Biotechnology, which is why Biotechnology sales missed consensus by ~3% even though its 5.0% core growth landed in line with the mid-single-digit guide and bioprocessing came in modestly above plan. Core growth of 3.0% sat at the top of the 2–3% guide, and core excluding respiratory of 5.5% beat the ~5% guide. The definitional point matters for comparability: starting this quarter, core sales exclude those customer refunds. On the old basis, core would have printed about 2.0%, at the bottom of the guide. We think the exclusion is defensible (the refunds unwind surcharges collected in earlier periods and say nothing about demand), but readers should know the comparison flatters by a point.

Margins: The real story of the beat. Adjusted operating margin of 29.0% rose 110bp year-over-year and beat the ~26.5% guide by 250bp, which management attributed "primarily" to operational execution, with a "modest benefit" from tariff refunds received. The company disclosed that the net earnings impact of IEEPA tariff refunds, after refunds passed to customers, was less than $100 million, so the refund contribution could range from small to a majority of the margin beat; management's characterization points to the smaller end. Gross margin of 58.5% rose 30bp year-over-year and 90bp sequentially. On a GAAP basis, operating margin slipped 10bp to 19.0%: Masimo's $84M inventory step-up (130bp), the dilutive effect of acquired businesses (125bp) and the special equity awards (20bp) outweighed higher core sales and tariff refunds (170bp) and lapping last year's impairments (85bp). The step-up, amortization and award expense are excluded from adjusted results.

EPS: Operational in direction, partly non-recurring in size. Adjusted EPS of $2.11 grew 11.6%, and the beat of $0.19 lines up almost exactly with the margin beat (250bp on $6.55B of sales, taxed at ~17%, is about $0.19 a share). Higher interest expense ($135M versus $67M a year ago, on Masimo debt) was only partly cushioned by interest income ($31M versus $3M) and a 1.0% lower share count. GAAP EPS of $1.71 included a $263M ($0.37 a share) discrete tax benefit from audit settlements, which is why GAAP EPS rose ~35% while adjusted EPS rose ~12%. Free cash flow of $1.63B (+19%) took year-to-date conversion to 128% of net earnings, the usual Danaher signature.

Segment Performance

Segment operating profit was $477M in Biotechnology (from $352M), $259M in Life Sciences (from $222M) and $614M in Diagnostics (from $665M), with unallocated corporate costs of ($105M) versus ($85M). The segment margins above are GAAP, so they carry acquisition amortization, impairments and the Masimo inventory step-up; the direction (Biotechnology and Life Sciences up, Diagnostics down on Masimo mix and purchase accounting) is the useful read.

Biotechnology: +5.0% Core, and the Bioprocessing Scare Fades

Biotechnology grew 5.0% core, a rebound from 2.5% in Q2 (though below Q1's 7.0%), while reported sales rose only 0.5% because tariff refunds returned to customers took about 4 points off segment sales and currency took another half point. Bioprocessing, the line that sank the stock in July, grew toward the upper end of mid-single-digits and came in modestly better than management expected. Consumables grew mid-single-digits, led by upstream consumables, and equipment grew low-single-digits, a second consecutive positive quarter after a long drought. Orders grew mid-teens again, led by upstream consumables and resins, and equipment orders are running at a strong double-digit rate year-to-date. Discovery & Medical declined low-single-digits, as solid protein-research instrumentation was more than offset by timing and lab consumables.

"Core revenue in bioprocessing grew towards the upper end of mid-single digits, modestly better than our expectations. Consumables were up mid-single digits, led by upstream consumables, while equipment increased low single digits… There is no change to our full year expectation of mid-single digit core revenue growth from bioprocessing." — Matt Gugino, EVP & CFO

Segment GAAP operating margin jumped 680bp to 26.4%. Of that, 490bp came from higher core sales, IEEPA tariff refunds and cost leverage net of mix, and 190bp from lapping last year's impairments. The refund component is not separately quantified, so some of the segment's margin step-up should be treated as non-recurring.

Assessment: This is the quarter the July bears needed to see go wrong, and it did not. There were no new push-outs, resin orders were specifically called out as strong (resin was the product deferred in Q2), and the full-year bioprocessing outlook held at mid-single-digits. Management expects bioprocessing growth rates to "continue to improve in 2027" and reaffirmed high-single-digit long-term growth for Cytiva. The Bear-1b visibility risk we added in July has eased materially. What is still missing is evidence that the ~$100M+ of deferred resin shipments returns on schedule in 2027; management did not update that figure.

Life Sciences: +4.5% Core, a Third Quarter Ahead of Plan

Life Sciences grew 4.5% core, a step down from Q2's 5.5% but above the 3–4% the company guided for the quarter, and management said it was the third quarter in a row the segment beat internal expectations. Pall's applied filtration business grew mid-single-digits on aerospace and microelectronics, slower than Q2's ~10% but still healthy. Life Sciences instruments grew mid-single-digits, led by SCIEX (strong pharma and biopharma demand, a modest pickup in U.S. academic spending, and the ZenoTOF 8600) and by Beckman Coulter Life Sciences, where automation is seeing demand for AI-enabled workflows. Consumables grew low-single-digits on IDT's MRD and next-generation-sequencing lines and an improving academic and pharma mix at Abcam. GAAP segment margin rose 150bp to 13.9%, including 45bp from the settlement of an acquisition-related contingency.

"Frankly, this is the third quarter in a row where Life Sciences has beat our internal expectations. The end markets continue to steadily improve. Large pharma and biopharma remained robust. Biotech funding is reading through. Academic demand, still below historic levels, but improved modestly sequentially." — Julie Sawyer Montgomery, President & CEO

Assessment: The July breakout was not a one-quarter pop, and the Q4 segment guide was raised to 4–5% (from 3–4%). The composition is the right kind: pharma and biopharma steady, biotech funding converting, academic stabilizing off a low base, and an AI-related automation demand stream that is small but real. The Pall deceleration from ~10% to mid-single-digits is worth watching only because microelectronics was the most secular growth vector in the segment; one quarter does not make a trend.

Diagnostics: +7.0% Ex-Respiratory, Masimo's First Full Quarter

Diagnostics sales rose 17.0% to $2,882M, almost entirely from Masimo (acquisitions added 16.5 points, roughly $400M). Core grew 0.5%, but excluding a ~650bp respiratory headwind it grew 7.0%, the segment's strongest underlying rate of the year. Clinical diagnostics grew mid-single-digits: Leica Biosystems was strong in digital pathology and advanced staining, and Beckman Coulter Diagnostics posted its best core growth in more than two years on the DxI 9000 and easing China policy headwinds. Cepheid's non-respiratory menu grew low-double-digits (group A strep, virology, sexual health). Respiratory revenue of ~$350M fell from ~$500M a year ago but beat plan, helped by customers stocking ahead of the season. Price was a 1.0% headwind in the segment, mostly China volume-based procurement and reimbursement changes.

"Beckman Coulter Diagnostics also delivered its highest core growth quarter in more than 2 years. The traction we saw from new product introductions, including the DxI 9000, together with easing China policy related headwinds, reinforces our confidence in Beckman's competitive position and ability to accelerate their growth trajectory." — Matt Gugino, EVP & CFO

GAAP segment margin fell 570bp to 21.3%: 365bp from the dilutive mix of acquired businesses and 295bp from Masimo's inventory step-up, partly offset by lapping a prior-year trade-name impairment (60bp) and higher core sales net of mix (30bp).

Assessment: Strip out respiratory and Diagnostics is now a high-single-digit grower in the clinical franchises, with Beckman re-accelerating and China finally turning positive. The problem is the part you cannot strip out of the P&L: respiratory keeps resetting lower, and the Q3 beat was partly customers buying ahead of the season, which the company itself flags as a risk to Q4 demand. Masimo is accretive to growth and dilutive to segment margin, as expected; StatLab joins the segment in Q4.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Measured, self-critical and forward-looking, a clear shift from the defensive, bioprocessing-centered posture of the July call. Management spent as much time on strategy and culture as on the quarter, and conceded openly that recent growth has fallen short of the portfolio's potential. Numbers were delivered conservatively: the 2027 framing was explicitly a "starting point," and respiratory was reset to a middle-of-the-road season, so the call was more convincing on direction than on near-term upside.

1. A New CEO and a Candid Diagnosis

This was Julie Sawyer Montgomery's first call as CEO. The board announced on August 3 that she would succeed Rainer Blair effective October 1; she joined Danaher in 2017 at Beckman Coulter Diagnostics and most recently ran the Diagnostics platform. Blair left the CEO role and the board on October 1 and stays on as senior advisor and then consultant through March 2027. Sawyer Montgomery opened with a long strategic preamble before touching the quarter, and its most notable line was an admission rather than a boast.

"At the same time, growth over the past several years has not consistently reflected the full potential of our portfolio. We've navigated significant changes in our markets, but regardless of the environment, we hold ourselves to a higher standard. We see a meaningful opportunity to accelerate sustainable core revenue growth, gain share more consistently, and more fully translate the strength of our portfolio into differentiated performance." — Julie Sawyer Montgomery, President & CEO

She set four priorities (commercial excellence, innovation, talent and capital allocation) and a unifying theme of a "more connected Danaher," keeping the operating-company structure while selling across it. The portfolio work, in her framing, is done: "our focus is shifting from reshaping the portfolio to delivering more growth from the businesses we own." She also said plainly that this "will take time, and we know credibility will be earned through results."

Assessment: The diagnosis is right, and it is unusual to hear it this directly from an insider promoted to the top job. It moves the debate from whether the cycle is turning to whether Danaher can take share, which is a better debate for a franchise with this portfolio. But it also sets expectations for a multi-year execution story, and the near-term financial signposts (Q4 guide, 2027 starting point) were deliberately unambitious. We read the first call as a credible reset of the narrative, not yet a reset of the numbers.

2. Core Ex-Respiratory Accelerates to 5.5%, and It Is Broad

The quarter's most important number is the second consecutive acceleration in core growth excluding respiratory: 3.0% in Q1, 4.5% in Q2 and 5.5% in Q3 (after 4.0% in Q4 2025). Every segment grew mid-single-digits or better on that basis (Biotechnology 5.0%, Life Sciences 4.5%, Diagnostics ex-respiratory 7.0%). Geographically, high-growth markets grew ~10% core, China grew high-single-digits with all three segments positive, and Western Europe grew mid-single-digits, while North America declined low-single-digits on respiratory.

"Sales were $6.6 billion and core growth, excluding respiratory revenue, was up 5.5%, an encouraging 100 basis points acceleration from the second quarter and a continuation of the improvement we have seen throughout the year." — Matt Gugino, EVP & CFO

Two caveats keep this from being an unqualified win. First, the easier comparison helps: Q3 2025 core ex-respiratory was only 2.5%, so the two-year stack is 8.0 points, and the Q4 guide of 4–5% against a 4.0% comparison implies a similar 8–9 point stack. Second, price was a 0.5% headwind company-wide, so volume did the work.

Assessment: This retires the narrow-core bear point we carried from initiation. Growth is no longer one segment and one region; it is three segments and most geographies. The two-year stacks say the underlying trend is improving steadily rather than spiking, which is the more durable kind of acceleration.

3. Bioprocessing: Better Than Feared, No New Deferrals

July's sell-off was a referendum on bioprocessing visibility after a few large customers deferred more than $100M of resin shipments into 2027. Q3 answered the near-term question well: bioprocessing grew toward the upper end of mid-single-digits, above plan; orders grew mid-teens for a second straight quarter, with resins named among the leaders; and the full-year bioprocessing outlook held.

"These underlying market trends, combined with Cytiva's differentiated portfolio, deep scientific expertise, and recent innovations, reinforce our confidence in the business' ability to deliver sustainable high single digit long-term revenue growth while helping customers improve yields, increase manufacturing efficiency, and scale new therapies." — Matt Gugino, EVP & CFO

Management cited a record number of monoclonal antibodies coming to market, biosimilars, and newer modalities (antibody-drug conjugates, cell therapy, bi- and tri-specifics) as secular drivers. Reshoring is a slower burn: brownfield projects are modestly helping orders today, while larger greenfield builds remain in planning and are "more of a 2028 plus event" for the P&L, in what management called a potential billion-dollar U.S. market opportunity.

Assessment: The bioprocessing pillar is back on solid footing. Mid-teens orders in two consecutive quarters, with resin strength, is hard to square with a demand problem, and we downgrade the July visibility risk from emerging to contained. The greenfield timeline (2028 and beyond) means reshoring is an option on the out-years, not a 2027 driver.

4. The Margin Beat and the Tariff Refund Question

Adjusted operating margin of 29.0% beat the ~26.5% guide by 250bp, worth roughly $0.19 a share, which is the entire EPS beat. The company's margin bridge credits higher core sales and IEEPA tariff refunds, net of mix and cost leverage, with 170bp of GAAP margin improvement, but does not split the two. The Supreme Court ruled in February that IEEPA did not authorize the tariffs, refunds began to flow, and Danaher both received refunds and returned some to customers.

"Our adjusted operating profit margin of 29% was up 110 basis points and exceeded expectations, driven primarily by strong operational execution with a modest benefit from tariff refunds received during the quarter." — Matt Gugino, EVP & CFO

The company disclosed that the net earnings impact of IEEPA refunds, after customer refunds, was less than $100 million. That is a wide band: at the top it would be about $0.14 a share, or most of the beat; at the bottom it is a rounding item. Management's "modest" points toward the bottom, and the Q4 margin guide of ~29.5% (+120bp year-over-year) suggests the underlying expansion is real.

Assessment: We give credit for the operating improvement but haircut the beat. The Biotechnology segment, where the customer refunds landed, booked a 490bp margin gain from core sales, refunds and cost leverage combined, which is too large to be all volume. Our FY27 estimate assumes no repeat of the refund benefit, and we would not extrapolate Q3's margin surprise into 2027 until the January guide shows it.

5. A New Definition of Core Sales

Starting with this quarter, Danaher excludes from core sales any tariff refunds it returns to customers for tariffs collected in prior periods. In Q3 those refunds cut reported sales by about 1.0% at the company level and about 4.0% in Biotechnology. Under the prior definition, company core growth would have been about 2.0% and Biotechnology core about 1.0%.

The company's rationale is that the refunds reverse tariffs collected in earlier periods and would otherwise obscure underlying trends, which is reasonable. Those earlier collections were not excluded from core at the time, so the treatment is asymmetric, but the dollars involved are small relative to the business.

Assessment: A defensible change made in the issuer's favor, in the quarter it first mattered. It does not alter our view of demand, which rests on the ex-respiratory trend and order data, but it is the reason we quote both definitions here. If refunds continue into Q4 and 2027, the gap between reported and core growth will persist and deserves continued disclosure.

6. Respiratory Resets Again, and the Q4 Exit Slips

Respiratory testing is now planned at ~$1.5B for 2026, down from "about $1.6 billion or a touch below" in July and ~$1.9B in 2025. Q3 respiratory of ~$350M beat plan, but partly because customers bought ahead of the season. Q4 respiratory is planned at ~$400M against ~$500M a year ago, a ~150bp headwind, where in July management had expected respiratory to wash out year-over-year in Q4. As a result, the Q4 exit rate for total core growth is now ~3.0%, not the mid-single-digit rate promised last quarter, and full-year core falls to ~2.5% from 3–4%.

"We are planning for $1.5 billion in respiratory this year, and I think that's also the right starting point for next year as well. Really what I want to do here is to create an expectation for a down the middle of the road flu season." — Julie Sawyer Montgomery, President & CEO

Management stressed that flu seasons swing by "a couple hundred million dollars" either way and that the season does not formally start until influenza-like illness crosses 3%, typically in late November or early December.

Assessment: This is the one commitment from July that missed: the mid-single-digit Q4 exit. The miss is entirely respiratory, and resetting to a middle-of-the-road season is the right planning choice for a new CEO. But it is the third downward respiratory revision this year (from ~$1.8B in January), and $1.5B as the 2027 base removes the comp tailwind investors had hoped would flatter next year's headline growth.

7. The 2027 Framework: A Starting Point, Not an Acceleration

Management offered a first look at 2027 ahead of January guidance: 4–5% core growth excluding respiratory as "the right starting point as we sit today," with respiratory flat at ~$1.5B. That implies total core growth of roughly 4–5% in 2027, up from ~2.5% in 2026, but no acceleration in the ex-respiratory rate from 2026's mid-single-digit pace.

"Excluding respiratory revenue, core revenue growth has averaged 4%-5% over the past several quarters. As we look to 2027, we think that 4%-5% core revenue growth, excluding respiratory revenue, is the right starting point as we sit today." — Matt Gugino, EVP & CFO

Several tailwinds are not obviously in the range: the deferred resin shipments, a full lap of China volume-based procurement, bioprocessing orders running mid-teens, and Life Sciences ahead of plan for three quarters. Management declined to say whether any were excluded, deferring to its normal fourth-quarter planning process.

Assessment: The framing looks conservative, and the Street will likely treat 5% as the real target. We do not think that makes it a positive catalyst. A new CEO who has just told investors that credibility will be "earned through results" has every incentive to set a January guide she can beat, and the company also has to absorb a full year of Masimo interest cost. We model 2027 core at ~4.5% and expect the upside, if it comes, to arrive through beats rather than a generous guide.

8. Life Sciences and the AI Workflow Opportunity

The new CEO gave AI unusual airtime, framing Danaher as one of few companies with all the building blocks for AI-driven drug discovery: instruments (Molecular Devices, SCIEX, Leica Microsystems), consumables (IDT, Abcam), automation (Beckman Life Sciences), software (Genedata, IDBS) and scale. Danaher announced its first AI-powered autonomous lab at Abcam, which it says moves researchers from idea to validated reagent up to 8 times faster at up to 10 times the volume, plus a collaboration with NVIDIA announced the prior week and work with Anthropic on instrument connectivity standards.

"While it is not material today, we have started to see a modest benefit to our orders and revenue. Frankly, it is at the forefront of every customer conversation I have in Life Science." — Julie Sawyer Montgomery, President & CEO

Assessment: Correctly sized: not material today, visible in Beckman Life Sciences automation orders, and a credible long-term reason for Life Sciences to grow faster than its academic-heavy history. We treat it as optionality, not as part of the 2027 base case.

9. Commercial Excellence and Selling as One Danaher

Sawyer Montgomery's most concrete near-term lever is commercial execution: tighter sales standards (what Danaher calls the commercial standard condition), more entrepreneurial decision-making, and cross-company selling to large customers who buy from several operating companies. She pointed to Diagnostics, where joint account teams have generated what she described as several hundred million dollars of opportunity in a short time, and to a similar approach with AI-native biotechs in Life Sciences.

"This approach has generated meaningful incremental revenue opportunities and is helping drive share gains across our Diagnostics businesses." — Julie Sawyer Montgomery, President & CEO

Assessment: The Diagnostics proof point (Beckman's best growth in two years, Diagnostics ex-respiratory at 7%) gives the strategy some credibility, and it was run by the person who now runs the company. The risk is the familiar one for decentralized conglomerates: cross-selling programs add coordination cost and incentive complexity before they add revenue. "Unambiguous share gain" is a good report card precisely because it will be hard to fake.

10. Masimo on Track, StatLab Closed, Buyback Paused

Masimo delivered high-single-digit growth in its first full quarter under Danaher ownership and year-to-date, contributed roughly $400M of Q3 revenue, has completed more than ten kaizens, and received its sixth FDA clearance of the year (the smartSET atrial-fibrillation detection platform). Leica Biosystems closed the ~$1.4B, cash-funded StatLab acquisition on September 28; StatLab joins Diagnostics in Q4. Danaher did not repurchase shares in Q3 (the $903M year-to-date was all first half), and quarter-end net debt was about $20.8B before the StatLab payment.

"M&A remains our bias for capital allocation as we think it is the best way to compound returns over the long term, and we are going to continue to look for strategically compounding M&A… I actually do not see that as a med tech M&A play. I see it as a continuous diagnostic that is strategically compounding with our Diagnostics business." — Julie Sawyer Montgomery, President & CEO

Assessment: The Masimo integration risk stays contained, and the new CEO, who led the deal, has every reason to make it work. With leverage elevated after two acquisitions in four months, we expect a quieter capital-deployment cadence near term: bolt-ons and debt reduction rather than another large deal or a large buyback. That removes one of the levers that supported our Outperform.

11. The Guide: EPS Up, Core Down, Q4 Below the Street

FY26 adjusted EPS guidance rose to $8.57–$8.62 from $8.45–$8.60, a $0.07 increase at the midpoint, implying ~10% growth over 2025's $7.80. With $6.11 earned through three quarters, the range implies Q4 EPS of $2.46–$2.51 (+10–13% year-over-year), against pre-print consensus near $2.59. Q4 adjusted operating margin is guided to ~29.5%, up 120bp from Q4 2025's 28.3%.

"For the full year 2026, we are increasing our full year adjusted diluted net EPS guidance to $8.57-$8.62 versus our prior range of $8.45-$8.60. This reflects the benefit of our third quarter outperformance and represents double digit year-over-year EPS growth." — Matt Gugino, EVP & CFO

Assessment: A beat-and-partial-raise. The raise retains about a third of the $0.19 Q3 beat against consensus, and the remainder effectively lowers Q4: the respiratory cut lands entirely in Q4, and some Q3 benefits (tariff refunds, pre-season respiratory buying) will not recur. Danaher's guidance habit is conservative, so Q4 can still beat the implied range, but the numbers now ask the Street to trim Q4 rather than raise it.

12. Governance: Founder Awards, a Waiver and a Board Refresh

Alongside the CEO change, Danaher granted special long-term growth awards on August 4: $20M of options to the new CEO, $12.5M to the CFO, RSUs to two other executives, and to each of founders Steven and Mitchell Rales options on 1,000,000 shares plus RSUs on 500,000 shares, all struck at the $194.78 grant-date close. On October 9 the Rales brothers waived the RSU portion for no consideration, which triggers a non-cash $185M charge in Q4 (excluded from adjusted EPS); the options remain. The same day, the board added former CFO Daniel Comas and biotech executive Robert Hershberg. None of this was discussed on the call.

Assessment: Not a thesis issue, but worth noting. Equity awards to billionaire founders who already own large stakes invite governance questions, and the quick partial waiver suggests the board heard them. The options (struck about $36 below the current price) align the founders with the stock, and the $185M charge is a one-time accounting item. We would rather the company had explained the rationale on the call than in a footnote.

Guidance & Outlook

The guide moved in two directions at once. EPS went up for the third time this year, reflecting the Q3 margin beat, while revenue-growth expectations came down, entirely because respiratory was reset to ~$1.5B. Underneath, the ex-respiratory outlook is unchanged at mid-single-digits for the year, Life Sciences was raised for Q4, and bioprocessing held. Management framed the 2027 view as an anchor rather than guidance and promised a "more quantitative and detailed" outlook in January.

Implied Q4: EPS of $2.46–$2.51 on ~29.5% adjusted margin and ~3% core growth (4–5% ex-respiratory). With Masimo and StatLab adding inorganic growth and currency roughly flat, the implied EPS growth of 10–13% is credible.

Street at: Roughly $2.59 for Q4 and $8.51 for FY26 before the print. The FY range now sits above the old full-year consensus, but adding the Q3 beat to the old numbers would have put the Street near $8.70, so Q4 estimates come down by about $0.10.

Guidance style: Conservative, consistent with Danaher's history and with a new CEO's incentives. Q3 margin was guided at ~26.5% and delivered at 29.0%. We expect the same posture in January, which argues for beats through 2027 but a modest starting guide.

Analyst Q&A Highlights

What Changes, and What Stays, Under the New CEO

The first question of the call asked the new CEO to reconcile Danaher's case-study legacy of operational excellence with the need for change. Her answer located the difference in the customer: the old model fit low-growth markets where customers bought from one operating company, while today's scientific customers buy across many, which argues for keeping the operating companies but selling as one company.

Q: "…how are you balancing the legacy of a company that has business school case studies written about its strategy and execution versus the opportunity and need to make change? Essentially, as you sit here today, what is foundational, and how do you think about evolving the playbook?"
— Doug Schenkel, UBS

A: "When that Harvard case study was written, our businesses were lower growth markets and our customers typically bought from a single operating company. We are in a very different situation today. Higher growth, scientific markets with the same customers buying across 3, 6, 12 operating companies. We will keep the advantages of our operating company structure in place."
— Julie Sawyer Montgomery, President & CEO

Assessment: A thoughtful answer that evolves the model rather than discarding it. The "connected Danaher" concept is an incremental change to how the company sells, not a reorganization, which lowers execution risk but also caps how quickly it can move the numbers.

How Investors Should Grade Progress

A follow-up asked which priority matters most over the next 12–18 months and which metrics investors should use to judge it. Management named commercial excellence and gave a clear, if non-numeric, report card: accelerated profitable growth and share gains.

Q: "What's the biggest one that you expect to have the greatest impact over the near term, say, over the next 12-18 months? What operating or financial metrics should investors use to assess progress pursuant to that top priority?"
— Doug Schenkel, UBS

A: "Step one is really prioritizing aligning our teams around accelerated profitable growth and unambiguous share gain as the report card, and that's what our investors should be looking for."
— Julie Sawyer Montgomery, President & CEO

Assessment: A good report card with no numbers attached. Share gain will be visible against peers (the largest peer reported 6% organic growth the same day against Danaher's 3% core), so the yardstick is measurable even if management did not quantify a target. We will hold the company to relative growth from here.

Can Bioprocessing Reach High-Single or Double-Digit Growth in 2027?

An analyst listed the 2027 tailwinds (strong equipment orders, onshoring, the catch-up from Q2's consumables push-out) and asked whether bioprocessing should run high-single to low-double-digits next year. The CFO held the 2026 line and pointed to improving growth in 2027 without putting a number on it.

Q: "I am curious, should bioprocessing be pushing very high singles, low double digits, when you think about fiscal 2027?"
— Vijay Kumar, Evercore ISI

A: "No change to our full year expectations for 2026 for bioprocessing, mid-single digit core growth. We saw Q3 was actually a bit better than we expected, the upper end of that mid-single digit range. From an orders perspective, they remain strong. Mid-teens order growth that was led by upstream consumables as well as resins. Given order trends and those order trends that we are seeing, we would expect to see bioprocessing growth rates continue to improve in 2027."
— Matt Gugino, EVP & CFO

Assessment: Directionally bullish and deliberately unquantified. "Continue to improve" from upper mid-single-digits points toward high-single-digits, which is consistent with the long-term Cytiva algorithm. Double-digit bioprocessing is the bull case and was not endorsed.

Stress-Testing the 4–5% Starting Point for 2027

The most pointed question of the call asked why 2027 ex-respiratory growth would be no faster than 2026 when the resin deferrals return, China procurement headwinds are lapped, and biotech and academic are improving. Management did not engage with the individual tailwinds and deferred to the January planning process.

Q: "I want to stress test the assumptions you put out for next year, the 4%-5%. I have a lot of people asking why you are not accelerating here… So, why on earth would ex-respiratory be the same?"
— Tycho Peterson, Jefferies

A: "As Matt discussed, we've delivered core growth ex respiratory in the 4%-5% range the last few quarters, so we think that's a reasonable starting point for 2027 based on the current end market conditions… We really want to work through our typical planning process here that we go through in Q4, then we will provide you a more quantitative outlook in January."
— Julie Sawyer Montgomery, President & CEO

Assessment: A non-answer, and a revealing one. Management did not claim anything was getting worse; it simply declined to bank tailwinds before its planning cycle. That reads as conservatism, but it also means there is no near-term guidance catalyst until January, and January is when a new CEO sets the bar.

Why Another Respiratory Cut, and What Is the New Endemic Base?

A follow-up challenged the ~$100M respiratory cut given that Q3 beat and recent data had begun to turn, and asked whether $1.5B is the right endemic rate. Management said it is planning for a middle-of-the-road season in both 2026 and 2027.

Q: "I understand weak flu season overall, but why another $100 million cut when the data's starting to turn here? 3Q came in above. Is that conservatism or are you seeing something in the data that leads to the cut here?"
— Tycho Peterson, Jefferies

A: "We are planning for $1.5 billion in respiratory this year, and I think that's also the right starting point for next year as well. Really what I want to do here is to create an expectation for a down the middle of the road flu season. As you know, there is variability in flu seasons year to year, season to season. Yes, that can create a couple hundred million dollars of bookends around that number."
— Julie Sawyer Montgomery, President & CEO

Assessment: The new CEO is resetting respiratory to a neutral base so it stops being a source of guidance misses. That is sensible, and with a ±$200M band around $1.5B, a normal or strong flu season is now upside. But it confirms that 2027 will not get a respiratory comp tailwind in the plan.

Making Commercial Execution Real: Incentives

An analyst asked what actually changes to drive commercial execution: compensation, people or process. The answer focused on simple sales standards and, most notably, on incentives for cross-company selling.

Q: "So what's the first step? Do you have to change compensation schemes? Do you have to change out people?"
— Scott Davis, Melius Research

A: "When we first started doing this in Diagnostics, one of our rules is when we have a solutions group team go out and talk to customers, no one's incentives are ever hurt. Frankly, the opportunity is clear enough here that I am happy to double pay on incentives because as you are using the power of Danaher to increase our share of wallet with customers, there is significant win-win opportunities there to go after."
— Julie Sawyer Montgomery, President & CEO

Assessment: The most concrete operational answer of the call. Paying twice for cross-selling removes the classic conglomerate turf problem, at a cost in selling expense. It is a reasonable trade if it produces share gains; it is a margin leak if it does not, and it is one more reason we expect the January guide to include some reinvestment.

M&A After Recent Misses

An analyst asked whether the M&A process needs to change after some recent deals underperformed, and how to keep deploying capital without freezing. Management said the process is sound, the lessons have been absorbed, and capital deployment remains a priority.

Q: "Do you feel the need to change the process?… So how do you keep that flywheel moving so that you are putting capital to work, but increase your hit rate from here?"
— Scott Davis, Melius Research

A: "We certainly don't want to freeze. Capital allocation remains a priority for us. Frankly, we have great processes and great teams for M&A. You mentioned some that haven't performed as well in the recent past, and I think as a company, we have learned from that."
— Julie Sawyer Montgomery, President & CEO

Assessment: An acknowledgment without specifics. The company has recorded sizable impairments in recent periods (including a $432M Life Sciences trade-name charge in the first nine months of 2025), and "strategically compounding" is a sensible filter. With leverage elevated after Masimo and StatLab, the practical answer for 2027 is likely smaller deals.

Equipment Orders, Pent-Up Demand and Reshoring

An analyst asked for the equipment component of mid-teens bioprocessing orders and how much reshoring could contribute in 2027. Equipment orders are running strong double-digits year-to-date, but the larger reshoring projects are later than some had hoped.

Q: "Then, maybe as a follow-up, you called out mid-teens order growth in bioprocessing. If you could maybe just double-click on the equipment piece of that order growth, maybe parse out how much pent-up demand you're seeing over the last several quarters."
— Casey Woodring, JPMorgan

A: "Also, when you think about equipment versus consumables orders year-to-date, both up nicely with those equipment orders continuing in that strong double-digit range… Those larger greenfield projects are still in the planning phases. The funnel and quoting activity is beginning to pick up, but we see that as more of a 2028 plus event in terms of when it starts to hit the P&L."
— Matt Gugino, EVP & CFO / Julie Sawyer Montgomery, President & CEO

Assessment: Strong double-digit equipment orders support equipment revenue growth into 2027 from a depressed base. Greenfield reshoring as a 2028-plus event removes it from next year's model. The equipment cycle is real but brownfield-led for now.

Life Sciences End Markets and Levers for 2027

The last question asked where each Life Sciences end market sits in its recovery and where upside could come from next year. Management described steady, broad improvement, with AI-driven workflows as the emerging lever.

Q: "Within Life Sciences, maybe walk through the key end markets of where we are in the recovery within academic and then biotech… any areas that investors should look for potential acceleration and levers for upside into next year?"
— Evie Koslosky, Goldman Sachs

A: "Frankly, this is the third quarter in a row where Life Sciences has beat our internal expectations. The end markets continue to steadily improve. Large pharma and biopharma remained robust. Biotech funding is reading through. Academic demand, still below historic levels, but improved modestly sequentially."
— Julie Sawyer Montgomery, President & CEO

Assessment: Three straight quarters above internal plan is a pattern, not noise. Academic remains the unrecovered piece, which means there is still upside if U.S. research funding normalizes. Life Sciences is the segment most likely to beat the 2027 starting point.

What They're NOT Saying

1. Where the deferred resin shipments stand: In July management sized more than $100M of resin shipments pushed into 2027. This call gave no update on whether any shipped in Q4, whether customers have confirmed 2027 timing, or whether the revenue sits inside the 4–5% 2027 starting point. It is the single most relevant follow-up to last quarter's sell-off, and it went unaddressed.
2. The size of the tariff refund benefit: The call described the refund benefit as "modest" and the company's filing caps it at under $100 million of net earnings, a band wide enough to cover anything from a rounding item to most of the EPS beat. Management did not say whether further refunds are expected in Q4 or 2027, or whether any are in the guide.
3. Why the FY raise is smaller than the Q3 beat: The implied Q4 of $2.46–$2.51 sits about $0.10 below the pre-print Street. Respiratory explains part of it; management did not walk through the rest (non-recurring Q3 items, Q4 investment, mix).
4. A company-wide long-term algorithm: Management reaffirmed high-single-digit long-term growth for Cytiva bioprocessing but did not restate a company-level long-term core growth or margin target. A new CEO who calls recent growth inadequate will eventually need to say what adequate is; the absence suggests that waits for January or an investor day.
5. The founder awards and the waiver: The special equity awards to the Rales brothers, the waiver of the RSU portion and the $185M Q4 charge were not mentioned on the call. Investors had to piece the story together from filings.
6. Why the CEO change happened now: The transition was framed as succession planning, and the call contained no discussion of the outgoing CEO's tenure or the board's reasoning on timing. The new CEO's critique of recent growth implicitly answers part of the question.
7. Masimo synergy and margin targets: Masimo is growing high-single-digits with a "healthy funnel" of cost and commercial synergies, but there was no quantification, and the segment margin bridge shows acquired businesses diluting Diagnostics margin by 365bp.

Market Reaction

• Pre-print setup: DHR closed at $224.24 on October 20, down 2.0% year-to-date against +12.7% for the S&P 500, but up 3.9% over the trailing 30 days and 1.6% over the trailing 12 months. The 52-week closing range was $161.91–$242.05. Since our July 21 note the stock had already rallied 25.3% from $179.01.
• Reaction (same-day, before-open print): Shares gapped down 3.0% to open at $217.56, then reversed through the session to a high of $234.40 and closed at $233.86, +4.3% (+$9.62), the highest close since the July print.
• Volume: 8.9M shares against a 4.3M 30-day average (2.0x), elevated but far below July's 6.7x washout.
• Benchmark and peers: The S&P 500 rose 0.6% on the day. The largest peer, which reported the same day with 6% organic growth, rose 1.0%; other tools names rose 0.4% to 3.3%. DHR outperformed the group.
• Following sessions: DHR fell 1.8% to $229.75 on October 22 and closed at $230.50 on October 23.
• Since our Q2 note: +30.6% from $179.01 to the reaction close, against +3.3% for the S&P 500 over the same span. Four tools peers we track rose 24.5% to 41.7% over the same period.

Gap-and-Reverse

The opening drop priced the obvious negatives first: a Q4 guide below the Street, another respiratory cut, a full-year core growth reduction and a 2027 framework that did not accelerate. As the call progressed, the market weighed those against a second straight acceleration in ex-respiratory growth, bioprocessing better than feared with no new deferrals, a 250bp margin beat and a new CEO whose message was candid and growth-focused. By the close, investors had decided the quality of the underlying trend outweighed the conservatism of the outlook, and the stock finished at its best level since the July sell-off.

The Sector Did Much of the Lifting

The more important context is the three months before the print. Since July 21, DHR has risen 30.6%, but the four tools peers we track rose between 24.5% and 41.7% over the same span, and the largest of them rose 32.6%. The tools sector has re-rated on improving pharma, biotech and bioprocessing demand, and DHR rode that wave. Measured from the day before the July print, DHR is up 16.3% while its largest peer is up 31.9%, so the July discount has closed in absolute terms but DHR still lags on a relative basis. The FY26 EPS guide midpoint rose only 0.8% over the period; nearly all of the stock's gain came from the multiple, which moved from ~21x to ~27x the FY26 guide.

That is the crux of our rating change. In July we argued the crater had done the bear case's work and left ~20% base-case upside. The stock has now traveled through our ~$214 base case to the top of our old $205–$235 fair-value range. What remains is a fairly valued compounder with improving fundamentals, a new CEO and a deliberately conservative outlook, at roughly its five-year average multiple.

Street Perspective

Debate: Is 4–5% for 2027 a Sandbag or a Ceiling?

Bull view: It is a sandbag. Ex-respiratory growth is already running 5.5%, the deferred resin shipments return in 2027, China procurement headwinds are lapped, bioprocessing orders are up mid-teens, and Life Sciences keeps beating plan. Bulls see a path to above-5% core growth driven by Cytiva approaching double digits, and a January guide that the company beats every quarter.

Bear view: It is a realistic midpoint. Q4 ex-respiratory is guided to slow to 4–5% from 5.5%, price is a headwind, the largest peer is growing twice as fast, and a new CEO has no reason to promise more. If the January guide lands at 4–5% with reinvestment, the stock has already priced the good version.

Our take: The bulls are probably right about the trajectory and wrong about the timing of the reward. We model ~4.5% core for 2027 and see upside in the second half, but we expect a conservative January guide, which makes the next two quarters a show-me period rather than a catalyst window.

Debate: Can Bioprocessing Return to High-Single or Double-Digit Growth?

Bull view: Two quarters of mid-teens orders, strong double-digit equipment orders, a record number of monoclonal antibodies coming to market, biosimilars, newer modalities and the returning resin shipments all point to high-single to double-digit bioprocessing in 2027, the engine that historically drove Danaher's premium multiple.

Bear view: Bioprocessing just proved in July that a few large customers can swing a quarter by hundreds of basis points, greenfield reshoring is a 2028-plus event, and management itself only committed to growth rates that continue to improve. High-single-digit growth is plausible; double-digit growth is a hope.

Our take: Lean bull on direction. The order data has been consistent enough that high-single-digit bioprocessing in 2027 is our base case. Double-digit growth would be the single biggest source of upside to our estimates, but we do not underwrite it at the current multiple.

Debate: Is the New CEO a Catalyst or a Reset Risk?

Bull view: An insider who ran the best-performing platform, with a clear focus on share gain, commercial excellence and AI-enabled workflows, and the credibility of having led the Masimo deal. Her candor about recent growth signals accountability, and a sharper commercial engine could lift the whole portfolio.

Bear view: New CEOs typically reset expectations, add investment and set beatable first-year guides. Double incentives for cross-selling, enterprise-level R&D bets and a talent push all cost money before they earn it. Governance noise around the founder awards does not help.

Our take: Both are true, sequentially. The strategy is sound and the messenger credible, but the payoff is a 2027–2028 story and the first financial expression of it, the January guide, is more likely to temper than to lift numbers.

Debate: Has the Re-Rating Run Ahead of the Fundamentals?

Bull view: No. The tools cycle is turning, Danaher's multiple is still only around its five-year average, and higher-quality growth in 2027–2028 justifies a premium. Price targets across the Street moved up after the print, and the stock still trails its largest peer since July.

Bear view: Yes. The stock is up ~30% while the EPS guide rose under 1%, and at ~27x current-year earnings for a business growing core ~2.5% this year and 4–5% next year, the valuation leaves little room for another respiratory or bioprocessing wobble.

Our take: The re-rating was justified by the improving trend, which is why we held through July. But it has now consumed the discount. At ~25x FY27 consensus EPS, the stock prices a credible recovery; it does not price an acceleration beyond guidance, and we no longer see enough asymmetry to stay at Outperform.

Model Update & Valuation Framework

Valuation framework: At $230.50 (the October 23 close), DHR trades at ~26.8x the $8.595 midpoint of the FY26 guide, up from ~21x on the same year's guide at our July note, and ~24.8x our $9.30 FY27 estimate (in line with consensus). Our base case applies ~26x to FY27E for a ~$242 fair value, about 5% above the current price, with a $235–$250 range (roughly 25–27x). The bull case (core ex-respiratory above 5.5% in 2027 on high-single to double-digit bioprocessing and continued Life Sciences beats, lifting FY27 EPS to ~$9.60 at ~28x) supports ~$270, about 17% upside. The bear case (a conservative January guide with visible reinvestment, another respiratory shortfall, and FY27 EPS of ~$9.00 at ~21x, the multiple we saw in July) implies ~$189, about 18% downside. A base case near 5% with roughly symmetric tails is a market-performing setup, not an outperforming one.

Signposts Into Q4 2026 and the January Guide

Thesis Scorecard: Grading the Q2 Commitments

In July we set seven commitments to grade this quarter. Five landed bullish, two were mixed, and none were outright misses. The one specific promise not kept, the mid-single-digit Q4 exit, failed on respiratory alone.

Updated Thesis Scorecard Post-Earnings

Overall: Operationally, the thesis strengthened. The bioprocessing pillar recovered from July's scare, the narrow-growth bear point is fading as all three segments grow mid-single-digits or better excluding respiratory, margins and cash flow remain best-in-class, and the Masimo risk stays contained. Two new risks enter: a respiratory base that keeps resetting lower, and a CEO transition that is strategically encouraging but likely to produce a conservative 2027 guide. The decisive change is not operational. The de-rated valuation that anchored our Outperform for four quarters has closed, with the multiple back near its five-year average.

Action: Downgrade to Hold from Outperform; conviction 6. The Outperform did its job: it was early and painful in July, and since then the stock has gained 30.6% against 3.3% for the market. From $230.50, our ~$242 base case implies ~5% upside with bull and bear cases roughly equidistant, which is market-performing risk/reward. We would revisit Outperform on a pullback toward the low $200s (about 22x FY27E) or on a January guide that frames 2027 core ex-respiratory at or above 5% with margin expansion intact.